Viridian Therapeutics, Inc , a biotechnology company, develops treatments for patients suffering from serious diseases.
infoViridian Therapeutics is a small cap stock with a total market cap of 829.73M.
infoThey trade on the NASDAQ and had their IPO 9 years and 2 months ago.
infoViridian Therapeutics currently employs 86 people.
infoAs of Wednesday, Aug 23 2023, Viridian Therapeutics’s share price is $19.0.
News Relating to Viridian Therapeutics
Zacks Investment Research
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates
Tuesday Aug 08 2023 at 18:56
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.06 per share a year ago.
The Motley Fool
2 Growth Stocks Wall Street Analysts Think Can Double in Value
Wednesday Jul 19 2023 at 10:07
Viridian has a treatment for thyroid eye disease in the works that could be a potential blockbuster. Ginkgo Bioworks programs cells and has huge opportunities in many different industries.
Seeking Alpha
Viridian: Despite Drop, Advancement Towards Phase 3 Continues
Thursday Jul 13 2023 at 15:16
There were positive results achieved from Viridian Therapeutics, Inc. phase 1/2 study using VRDN-001 for the treatment of patients with chronic thyroid eye disease. Initiation of the phase 3 THRIVE-2 study, using VRDN-001 for the treatment of patients with chronic thyroid eye disease, is expected by Q3 of 2023. Results from the phase 3 THRIVE-2 study, using VRDN-001 for the treatment of patients with chronic thyroid eye disease, are expected by end of 2024.
The Motley Fool
Why Shares of Viridian Therapeutics Are Falling Tuesday
Tuesday Jul 11 2023 at 12:20
Viridian said its lead therapy helped reduce bulging eyes in thyroid eye disease patients. The biotech specializes in rare diseases and immune disorders.
The Motley Fool
Why These 2 Nasdaq Biotech Stocks Fell Hard Tuesday Morning
Tuesday Jul 11 2023 at 09:26
Futures on the Nasdaq inched higher Tuesday morning. Viridian fell despite announcing some favorable early results from a clinical trial.
Market Watch
Viridian stock falls more than 15% after drug study update
Monday Jul 10 2023 at 16:55
Shares of Viridian Therapeutics Inc. VRDN, +5.06% fell in the extended session Monday after the biotech drug maker said it was making changes to its study design for a chronic thyroid eye disease therapy. Viridian shares fell more than 17% after hours, following a 5.1% rise to close the regular session at $24.52.
Seeking Alpha
Viridian Therapeutics, Inc. (VRDN) Q1 2023 Earnings Call Transcript
Saturday May 13 2023 at 18:02
Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Louisa Stone – Manager, IR Scott Myers – President and CEO Kristian Humer – Chief Financial and Business Officer Dr. Thomas Ciulla – Chief Development Officer Todd James – SVP, Corporate Affairs and IR Conference Call Participants Derek Archila – Wells Fargo Gavin Clark-Gartner – Evercore ISI Thomas Smith – SVB Securities Laura Chico – Wedbush Securities Kalpit Patel – B. Riley Securities Jason Butler – JMP Securities Rami Katkhuda – LifeSci Operator Welcome to the Viridian Therapeutics First Quarter 2023 Conference Call.
Zacks Investment Research
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates
Tuesday May 09 2023 at 18:20
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.61 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.98 per share a year ago.
Seeking Alpha
Viridian: A Second Buying Opportunity, But I Am Waiting For A Better Price
Tuesday Apr 11 2023 at 15:20
Viridian Therapeutics, Inc. has been a profitable investment for me. I am trying to get in again.
Seeking Alpha
Viridian Therapeutics, Inc. (VRDN) Q4 2022 Earnings Conference Call
Wednesday Mar 08 2023 at 14:46
Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q4 2022 Earnings Conference Call March 8, 2023 8:00 PM ET Company Participants Louisa Stone – Manager, Investor Relations Scott Myers – President and Chief Executive Officer Kristian Humer – Chief Financial Officer Deepa Rajagopalan – Chief Product and Strategy Officer Todd James – Senior Vice President, Corporate Affairs and Investor Relations Conference Call Participants Gavin Clark-Gartner – Evercore ISI Laura Chico – Wedbush Securities Jason Butler – JMP Securities Sam Slutsky – LifeSci Capital Kalpit Patel – B. Riley Securities Douglas Tsao – H.C.
Zacks Investment Research
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates
Wednesday Mar 08 2023 at 09:47
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -56.94% and 85.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023
Wednesday Mar 01 2023 at 08:00
WALTHAM, Mass., March 01, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Wednesday, March 8, 2023 at 8:00 a.m. ET to discuss its fourth quarter and full year 2022 financial results.
Seeking Alpha
Why Viridian Therapeutics Is One Of My 2023 Top Picks
Wednesday Jan 25 2023 at 13:14
Viridian was one of my top picks in 2022 and it made the 2023 list again. VRDN-001 data continue to impress and Viridian looks well-positioned to disrupt the thyroid eye disease market later this decade.
GlobeNewsWire
Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference
Tuesday Jan 03 2023 at 08:00
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that its President and Chief Executive Officer, Jonathan Violin, Ph.D., will present an overview of the company along with its upcoming corporate priorities at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 2:15 p.m. PST / 5:15 p.m. EST in San Francisco, California.
Seeking Alpha
MDA Breakout Stocks Week 1 – January 2023: High-Frequency Gainers To Give You An Edge
Monday Jan 02 2023 at 10:12
Two new Breakout Stocks for Week 1 with better than 10% short-term upside potential and two Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. The streak of weekly picks gaining over 10% in less than a week of trading days has reached 235 out of 293 trading weeks (80.4%) not counting multiple gainers.
Seeking Alpha
Viridian: Better Data Than A Blockbuster Competitor
Thursday Dec 15 2022 at 08:00
Viridian Therapeutics, Inc.’s data in TED beats Tepezza’s trial data. Tepezza is a blockbuster drug.
Seeking Alpha
Viridian Therapeutics, Inc. (VRDN) Q3 2022 Earnings Call Transcript
Monday Nov 14 2022 at 14:08
Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants John Jordan – Vice President of Investor Relations Jonathan Violin – President & Chief Executive Officer Barrett Katz – Chief Medical Officer Kristian Humer – Chief Financial Officer & Chief Business Officer Conference Call Participants Rami Katkhuda – LifeSci Capital Gavin Clark-Gartner – Evercore ISI Thomas Smith – SVB Securities Laura Chico – Wedbush Securities Kalpit Patel – B. Riley Securities Jason Butler – JMP Securities Operator Greetings and welcome to Viridian Therapeutics Third Quarter 2022 Earnings Call.
Zacks Investment Research
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates
Monday Nov 14 2022 at 09:47
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of 1.15% and 131.59%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market
Friday Sep 09 2022 at 08:00
Viridian’s phase 1/2 data was better than blockbuster competitor drug Tepezza’s data. The company is well-funded.
Investors Business Daily
Why Viridian’s CEO Isn’t Sweating His Company’s Second-Place Position
Wednesday Aug 31 2022 at 08:00
Viridian Therapeutics hopes to follow Horizon Therapeutics with a best thyroid eye disease drug, and the IPO stock is on a run. The post Why Viridian’s CEO Isn’t Sweating His Company’s Second-Place Position appeared first on Investor’s Business Daily.
InvestorPlace
Viridian Therapeutics (VRDN) Stock Jumps 60% on Promising Clinical Trial
Monday Aug 15 2022 at 14:50
Representing one of the top performers on Monday, shares of Viridian Therapeutics (NASDAQ: VRDN ) skyrocketed as much as 60%. The biotechnology firm released encouraging results for its therapeutic focusing on thyroid eye disease (TED), a rare autoimmune disease.
Schaeffers Research
Options Traders Blast Surging Biotech Stock After Earnings
Monday Aug 15 2022 at 14:17
The shares of Viridian Therapeutics Inc (NASDAQ:VRDN) are up 59.5% at $23.50 at last check, despite the company reporting wider-than-expected second-quarter losses of $1.06 per share.
Seeking Alpha
Viridian Therapeutics, Inc. (VRDN) CEO Jonathan Violin on Q2 2022 Results – Earnings Call Transcript
Monday Aug 15 2022 at 13:52
Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q2 2022 Earnings Conference Call August 15, 2022 8:00 AM ET Company Participants John Jordan – VP of IR Jonathan Violin – President and CEO Barrett Katz – Chief Medical Officer, Raymond Douglas – Director of Thyroid Eye Disease Kristian Humer – CFO and Chief Business Officer Conference Call Participants Chris Howerton – Jefferies Thomas Smith – SVB Securities Gavin Clark-Gartner – Evercore ISI Rami Katkhuda – LifeSci Capital Laura Chico – Wedbush Securities Kalpit Patel – B. Riley Securities FBR Jason Butler – JMP Securities Trevor Allred – Oppenheimer Michael Higgins – Ladenburg Thalmann Operator Greetings, and welcome to the Viridian Therapeutics Conference Call.
Investors Business Daily
New Contender Viridian Takes Aim At Horizon’s Eye Drug, And Rockets
Monday Aug 15 2022 at 11:32
Viridian unveiled promising results Monday for its Horizon-rivaling thyroid eye disease treatment — and the biotech stocks diverged. The post New Contender Viridian Takes Aim At Horizon’s Eye Drug, And Rockets appeared first on Investor’s Business Daily.
Zacks Investment Research
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates
Monday Aug 15 2022 at 09:47
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -23.26% and 63.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
Viridian Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call on August 15, 2022
Monday Aug 08 2022 at 08:00
WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from the second quarter ended June 30, 2022, before the financial markets open on Monday, August 15, 2022.
GlobeNewsWire
Viridian Therapeutics to Participate in June Investor Conferences
Wednesday Jun 01 2022 at 08:00
WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will participate in two fireside chats at the Jefferies Healthcare Conference being held in New York on June 8 -10, 2022 and the JMP Securities Life Sciences Conference in New York on June 15 – 16, 2022.
Seeking Alpha
Viridian Therapeutics, Inc. (VRDN) CEO Jonathan Violin on Q1 2022 Results – Earnings Call Transcript
Thursday May 12 2022 at 20:32
Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants John Jordan – VP, Investor Relations and Corporate Communications Jonathan Violin – CEO, President & Director Kristian Humer – CFO, Chief Business Officer, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Christopher Howerton – Jefferies Thomas Smith – SVB Leerink Laura Chico – Wedbush Securities Rami Katkhuda – LifeSci Capital Jason Butler – JMP Securities Operator Welcome to the Viridian Therapeutics First Quarter 2022 Conference Call. [Operator Instructions].
Zacks Investment Research
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates
Thursday May 12 2022 at 18:48
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -6.52% and 66.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
Viridian Therapeutics’ (VRDN) CEO Jonathan Violin on Q4 2021 Results – Earnings Call Transcript
Thursday Mar 10 2022 at 22:30
Viridian Therapeutics’ (VRDN) CEO Jonathan Violin on Q4 2021 Results – Earnings Call Transcript
Viridian Therapeutics Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Viridian Therapeutics’s Altman Z-score is 10.66 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
Viridian Therapeutics Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has sold $250.48K of common stock in Viridian Therapeutics on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Viridian Therapeutics’s Income Quality of 0.84 is greater than its Industry Group of 0.51 (64.7% greater)
Viridian Therapeutics’s Income Quality of 0.84 is greater than its Major Industry Group of 0.51 (64.7% greater)
Viridian Therapeutics’s Income Quality of 0.84 is greater than its Sector of 0.5 (68.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Viridian Therapeutics’s Current Ratio of 12.09 is greater than its Industry Group of 2.83 (327.2% greater)
Viridian Therapeutics’s Current Ratio of 12.09 is greater than its Major Industry Group of 1.56 (675.0% greater)
Viridian Therapeutics’s Current Ratio of 12.09 is greater than its Sector of 1.59 (660.4% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-4.28 & -1.1)
Cannot compare a negative PE Ratio (-4.28 & -0.48)
Cannot compare a negative PE Ratio (-4.28 & -0.29)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Viridian Therapeutics’s PB Ratio of 2.63 is greater than its Industry Group of 1.33 (97.7% greater)
Viridian Therapeutics’s PB Ratio of 2.63 is greater than its Major Industry Group of 1.42 (85.2% greater)
Viridian Therapeutics’s PB Ratio of 2.63 is greater than its Sector of 1.88 (39.9% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Viridian Therapeutics’s ROE of -0.61 is greater than its Industry Group of -0.9 (32.2% greater)
Viridian Therapeutics’s ROE of -0.61 is lower than its Major Industry Group of -0.21 (-190.5% lower)
Viridian Therapeutics’s ROE of -0.61 is lower than its Sector of -0.04 (-1425.0% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Viridian Therapeutics’s ROCE of -0.65 is in line with its Industry Group of -0.72 (9.7% greater)
Viridian Therapeutics’s ROCE of -0.65 is lower than its Major Industry Group of -0.23 (-182.6% lower)
Viridian Therapeutics’s ROCE of -0.65 is lower than its Sector of -0.02 (-3150.0% lower)
Derived from SEC.GOV filing dataopen_in_new